Prime Medicine Inc (PRME)
6.925
-0.02
(-0.22%)
USD |
NASDAQ |
May 24, 16:00
7.21
+0.28
(+4.12%)
After-Hours: 07:58
Prime Medicine Research and Development Expense (Quarterly): 37.77M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 37.77M |
| December 31, 2023 | 41.46M |
| September 30, 2023 | 40.97M |
| June 30, 2023 | 34.60M |
| March 31, 2023 | 30.88M |
| December 31, 2022 | 29.06M |
| Date | Value |
|---|---|
| September 30, 2022 | 25.05M |
| June 30, 2022 | 18.94M |
| March 31, 2022 | 13.68M |
| December 31, 2021 | 52.89M |
| September 30, 2021 | 7.40M |
| December 31, 2019 | 0.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.92M
Minimum
Dec 2019
52.89M
Maximum
Dec 2021
27.80M
Average
29.97M
Median
Research and Development Expense (Quarterly) Benchmarks
| Verve Therapeutics Inc | 48.38M |
| PetMed Express Inc | -- |
| 10x Genomics Inc | 68.64M |
| Sana Biotechnology Inc | 94.46M |
| Recursion Pharmaceuticals Inc | 67.56M |